Melanie Pars, PhD, MBA
About Melanie Pars, PhD, MBA
Melanie Pars, PhD, MBA, serves as the Director and Medical Lead for the DACH region at Deciphera Pharmaceuticals. With extensive experience in medical affairs across various organizations, she has held significant roles at Takeda Oncology, Novartis, and Adrenomed AG.
Current Role at Deciphera Pharmaceuticals
Melanie Pars serves as the Director, Medical Lead DACH at Deciphera Pharmaceuticals. She has held this position since 2021, contributing to the company's medical strategy and operations in the DACH region. Her role involves overseeing medical affairs and ensuring alignment with the company's objectives in the oncology sector.
Previous Experience at Takeda Oncology
Before joining Deciphera Pharmaceuticals, Melanie Pars worked at Takeda Oncology as the Manager of Medical Affairs Strategy & Operational Excellence from 2016 to 2020. During her four years in this role, she was based in Berlin and focused on enhancing the operational effectiveness of medical affairs within the organization.
Educational Background
Melanie Pars has an extensive educational background. She earned her Executive MBA from the Quantic School of Business and Technology in 2020. She completed her Ph.D. at Freie Universität Berlin from 2008 to 2011. Additionally, she holds a Diplom from the same university, which she achieved from 2000 to 2006. Her studies also include a year at the University of Cambridge in 2004-2005.
Career Development at Novartis
Melanie Pars has held multiple positions at Novartis, contributing to her professional development in the pharmaceutical industry. She worked as a Medical Trainee from 2011 to 2012, followed by roles as a Medical Advisor in Dermatology from 2012 to 2014 and as a Field Based Medical Advisor in Oncology from 2014 to 2016. Her experience at Novartis spanned various locations, including Nuremberg and Hannover.
Research Experience
Melanie Pars has a solid foundation in research, having worked as a Research Assistant at Imperial College London from 2006 to 2007 and as a Research Fellow at both Charité in 2004 and the Gurdon Institute in 2005. These roles provided her with valuable insights into scientific research methodologies and practices.